Remepy, a pioneer in hybrid drugs, has announced that the phase 2a clinical trial of Hybridopa, a new hybrid drug for Parkinson’s disease, met its primary endpoint, delivering statistically significant improvements across motor and non-motor outcomes in Parkinson’s disease.
The double-blind, placebo-controlled, randomized results demonstrate the ability of Hybridopa to enhance the clinical impact of standard levodopa therapy. The findings were published in Brain Communications in a paper titled ‘Neural correlates of Parkinson’s improvements after combined digital-levodopa therapy: a pilot study’. Hybrid drugs are a new class of drugs that combine traditional pharmaceuticals with mechanistically proven app-delivered personalised digital interventions into a single prescription.
The three-week, randomised, double-blind, placebo-controlled phase 2a clinical trial (n=41) evaluated Hybridopa in patients aged 45–80 with Parkinson’s disease. Participants were all on an unchanged dose of levodopa (ranging 150-1500mg daily), combined with DopApp™ or with a placebo digital application. The intervention consisted of a multi-modal daily digital protocol enabling structured, multidisciplinary care to be administered consistently in patients’ home environments.
Key clinical highlights
Significant motor and functional improvements – participants who received Hybridopa achieved a mean reduction of 9.7 points on the MDS-UPDRS Parts I+II+III, compared to a 1.95-point reduction in the control group (p=0.0005), demonstrating a robust improvement beyond levodopa therapy alone.
High responder rates – 90% of Hybridopa participants achieved at least a reduction of five-points in the MDS UPDRS Parts 1+2+3), substantially exceeding response rates in the control arm.
Objective neurobiological findings – advanced neuroimaging via functional MRI revealed strengthening of functional connectivity in motor and limbic brain circuits, correlating with improvements in both motor control and mood-related outcomes. These findings provide early mechanistic evidence that the digital component may reinforce dopaminergic treatment through targeted neuroplasticity.
Engagement-linked outcomes – greater engagement with specific DopApp modules corresponded with domain-specific clinical improvements, highlighting the importance of personalised digital interaction in driving therapeutic outcomes.
Diverse patient population – the study population included patients with diverse disease profiles, yet the integrated therapy demonstrated consistent benefit across the cohort, suggesting the potential to impact a broad Parkinson’s population.
